REALM IDx Inc.

Dr Luo also co-founded and served as Chairman of the board of Avida Biomed, an NGS-based liquid biopsy technology company that was acquired by Agilent in 2022. Dr Luo is a Venture Partner of Illumina Ventures. Steve brings to Alamar over 20 years of experience in technology innovation and management in biotech and high-tech industries. Prior to ACD, Steve co-founded Genospectra, served as its CTO and led the development of its microarray instrumentation systems. Xiao-Jun is a successful R&D leader with more than 20 years of experience in the life sciences and molecular diagnostics industries. Yiyuan brings to Alamar over 10 years of experience in antibody discovery and engineering. Berdine is a seasoned veteran of the life science industry and has over 20 years’ experience in biotech strategy development, product management, and marketing. Berdine has a successful track record of commercializing innovative technologies and extensive experience building while leading commercial organizations to support rapid growth.

At AcuamarkDX, we are shaping a new future in cancer diagnostics and making early cancer detection a standard of primary care. AcuamarkDx is pleased to be featured as a diagnostics company on the rise in the premiere issue of ENMEDIA magazine. Cochrane is the Chair of UNC’s Board of Trustees. Director R&D, Applied Biosystems Inc.; SVP Product Development & CTO, Helicos BioSciences Corp.; SVP R&D, Affymetrix; Independent Consultant. Director, Clinical Affairs and Regulatory Submissions at Abbott Molecular Diagnostics, at Baxter as Director of Clinical Affairs, at Oncor and at Boehringer Mannheim. Flom has led for over 30 products through regulatory filings and registration in the US and numerous international product registrations. Howard is a senior entrepreneurial executive with thirty-years of experience in operations, finance, business development, and investor relations at biotechnology companies. Founded UniTaq Bio to commercialize novel methods for highly multiplexed qPCR for diagnostics.

Kermani is the Founder and CEO of Crystal Genetics, Inc. Mark Baudler is a partner at Wilson Sonsini Goodrich & Rosati (WSGR). Mark Sutherland is the Founder and Principal of Sutherland Life Sciences LLC, a consulting firm which provides business consulting services to a wide variety of Life Sciences, Genomics, Molecular Diagnostics, Immuno-Oncology and Biotechnology companies. Arnold Oliphant is the CTO of Omniome, and is responsible for leading the research and development of Omniome’s sequencing technology. Yeung founded Triware Networld Capital, a Venture Capital and Investment firm. Pirooz Parvarandeh is the Chief Operating Officer at Aquantia (NYSE: AQ). Kamran Tahamtanzadeh (President & Chief Executive Officer of Inanovate Inc a leading proteomics company developing the world’s first multimodal-multiplexing protein measurement platform for disease diagnostics applications, former CEO of EpiCELONA, LLC and Founding CEO at PrognosDx Health, Inc a pioneering Cancer Epigenetics company), is an internationally recognized business executive with focus on Life Sciences, Molecular Diagnostics, Clinical Diagnostics and Medical Oncology market segments. Cancer screening is the first line-of-defense in detecting this disease early, and consequently changing its outcomes, dramatically.

Our mission is to build a leading molecular diagnostics company focused on developing minimally invasive solutions for early detection and monitoring of brain and synaptic health conditions, including mild cognitive impairment and Alzheimer’s disease, to enable earlier intervention and better planning of care. Mireskandari has over 12 years of life sciences industry experience with a focus on molecular diagnostic test development and commercialization, including regulatory and reimbursement expertise. Kumar is an accomplished research & development leader, with experience in leading CLIA facility operations. Kumar has 20+ years of experience in the development of technologies for molecular diagnostic and other applications. Kenny Ablordeppey serves as the Laboratory Supervisor and Project Manager at DiamiR. Rinder is a volunteer for the ASCP, serving on committees tasked with education and professional development, and currently is President of the ASCP, serving the pathology and laboratory professional workforce. Robert Rissman, PhD, is a Professor of Neurosciences at the University of California San Diego (UCSD), a Research Biologist at VA San Diego, Founding Director of UCSD’s Alzheimer's Disease Cooperative Study (ADCS) Biomarker Core, as well as, Founding Director of the Biomarker Core for University of Southern California (USC) Alzheimer’s Therapeutic Research Institute (ATRI) in San Diego. Mikhail Denissenko has over 20 years of experience in Diagnostics and Drug Discovery.

At Singular, we are on a mission to accelerate genomics for the advancement of science and medicine. Laure joined Singular Genomics with more than 18 years of experience in scientific customer support for the life science industry. Fong cofounded several companies including FWB LLC (acquired by Streamlogic), Techbargains.com LLC (acquired by Exponential), and Keyhole Therapeutics. Elaine Mardis is a pioneering researcher internationally recognized in cancer genomics with a focus on the application of genomic technologies to improve the understanding of human disease and the precision of medical diagnosis, prognosis and treatment. Prior to that, Jason served as the CFO of Foundation Medicine, a transformative company in oncology molecular profiling. Kamdar is a Managing Partner at Domain Associates, a venture capital fund focused on healthcare company creation. Kim is the author of ten papers as well as the inventor on seven patents. Mike is a Managing Partner of Section 32, a venture capital fund investing at the frontiers of technology, healthcare and life sciences.

With more than 20 years of experience in strategic business development for medical device and diagnostic companies ranging from start-ups to mature global corporations, Erik most recently served as Vice President of Business Development at Atonarp, Inc., and previously as Head of Business Development for Thermo Fisher Scientific, and previously as Senior Vice President of Business Development and Product Management at Mesa Biotech prior to its acquisition by Thermo Fisher. Slava Elagin brings to Alveo more than 20 years of experience in the in vitro diagnostics and medical devices industry. Food & Drug Administration clearances and commercialization and is the author on 12 U.S. John, a seasoned Manufacturing Operations Leader, spans small startups to industry giants like Flextronics, Mars Petcare, and Tesla Motors, showcasing expertise in management, manufacturing, and logistics. Kevin Gunning oversees Alveo’s Quality Management System and holds more than 25 years of experience working in the medical device, pharmaceutical, biotechnology and clinical laboratory industries. Mary McFillin is a senior global product marketing manager with extensive experience in the point-of-care diagnostics industry, leading strategy, development and support of in vitro diagnostics medical devices throughout the product life cycle. As a senior product management executive, Mary leads Alveo’s strategic marketing and target market development. Matthew Marsh has nearly 25 years of experience driving growth and value creation for customers, employees and shareholders.